Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 111 to 120 of 2450 total matches.
In Brief: A New Prostate Cancer Indication for Darolutamide (Nubeqa) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 19, 2023 (Issue 1679)
of nonmetastatic castration-resistant
prostate cancer (nmCRPC).1
MECHANISM OF ACTION — Androgen receptors ...
The androgen receptor inhibitor darolutamide
(Nubeqa – Bayer) has been approved by the FDA
for use in combination with docetaxel for treatment
of metastatic hormone-sensitive prostate cancer
(mHSPC). The drug was previously approved for
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC).
Med Lett Drugs Ther. 2023 Jun 19;65(1679):e108 doi:10.58347/tml.2023.1679h | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
.1
Treatment of pain when it is still mild to moderate in
intensity improves headache response ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Comparison Table: Triptans for Migraine (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
6.25, 12.5 mg tabs
20, 40 mg tabs 2.5 mg tabs 1, 2.5 mg tabs 5, 10 mg tabs, ODTs Imitrex and generics ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9 doi:10.58347/tml.2023.1678b | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
mg/day over 4 wks:
wk 1: 25 mg in the
evening;
wk 2: 25 mg in the
morning and evening;
wk 3: 25 ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2 doi:10.58347/tml.2023.1678c | Show Introduction Hide Introduction
Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
or refractory follicular
lymphoma, a common subtype of non-Hodgkin's
lymphoma.1
Pronunciation Key ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for subcutaneous
treatment of relapsed or refractory diffuse large
B-cell lymphoma (DLBCL), not otherwise specified,
including DLBCL arising from indolent lymphoma,
and high-grade B-cell lymphoma after ≥2 lines
of systemic therapy. Epcoritamab is the second
T-cell-engaging bispecific antibody to become
available in the US for treatment of non-Hodgkin's
lymphoma; mosunetuzumab-axgb (Lunsumio) was
recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4 doi:10.58347/tml.2023.1678d | Show Introduction Hide Introduction
Sotorasib (Lumakras) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
. Sotorasib is the
first KRAS inhibitor to be approved in the US.
chemotherapy and a programmed death 1 (PD ...
Sotorasib (Lumakras — Amgen), an oral KRAS
inhibitor, has received accelerated approval by the
FDA for treatment of KRAS G12C-mutated locally
advanced or metastatic non-small cell lung cancer
(NSCLC) in adults who received at least one prior
systemic therapy. Accelerated approval was based
on the overall response rate and duration of response.
KRAS mutations are found in 25-30% of non-squamous-cell NSCLC cases and the G12C mutation
is the most common KRAS mutation. Sotorasib is the
first KRAS inhibitor to be approved in the US.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e104-5 doi:10.58347/tml.2023.1678e | Show Introduction Hide Introduction
In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
in 2017 for
treatment of relapsed or refractory B-cell precursor
ALL in patients ≤25 years old.1 ...
Brexucabtagene autoleucel (Tecartus – Kite) has
been approved by the FDA for treatment of adults
with relapsed or refractory B-cell precursor acute
lymphoblastic leukemia (ALL). It was previously
approved for treatment of relapsed or refractory
mantle cell lymphoma. Tecartus is an individualized
cellular product prepared from the patients own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. The CAR T-cell immunotherapy
tisagenlecleucel (Kymriah) was approved in 2017 for
treatment of relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e105-6 doi:10.58347/tml.2023.1678f | Show Introduction Hide Introduction
Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
of tyrosine kinase inhibitors will need a change
in their treatment regimen by 5 years.1
MECHANISM OF ACTION ...
Asciminib (Scemblix – Novartis), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with Philadelphia chromosome-positive
chronic myeloid leukemia (Ph+ CML) in chronic
phase (CP) previously treated with ≥2 tyrosine kinase
inhibitors and for adults with Ph+ CML in CP with a
T315I mutation.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e107-8 doi:10.58347/tml.2023.1678g | Show Introduction Hide Introduction
In Brief: Two Doses of Jynneos for Mpox (online only)
The Medical Letter on Drugs and Therapeutics • Jun 02, 2023 (Issue 5065)
Table 1) receive two doses of
the Jynneos vaccine. The recommendation follows
reports of a recent ...
The CDC is recommending that persons at high
risk of mpox (see Table 1) receive two doses of
the Jynneos vaccine. The recommendation follows
reports of a recent cluster of mpox cases in the US
and warnings about the risk of a renewed outbreak
during the spring and summer as people gather
for festivals and other events. The CDC does not
recommend routine immunization against mpox for
the general population.
Med Lett Drugs Ther. 2023 Jun 2;65(5065):1-2 doi:10.58347/tml.2023.5065a | Show Introduction Hide Introduction
COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
is the first anti-C5a antibody to become
available in the US.1
STANDARD TREATMENT ― The NIH recommends ...
The investigational anti-complement component 5a
(C5a) antibody vilobelimab (Gohibic – InflaRx) has
been granted an FDA Emergency Use Authorization
(EUA) for IV treatment of hospitalized adults
with COVID-19 beginning within 48 hours after
invasive mechanical ventilation (IMV) or extracorporeal
membrane oxygenation (ECMO) is started.
Vilobelimab is the first anti-C5a antibody to become
available in the US.
Med Lett Drugs Ther. 2023 May 29;65(1677):86-7 doi:10.58347/tml.2023.1677d | Show Introduction Hide Introduction